CDC Meeting on RSV Vaccines Could Be Pivotal for GSK, Moderna | Barron's

Retrieved on: 2024-02-26 19:24:03

Tags for this article:

COVID-19 vaccination in the United States

RNA vaccines

COVID-19 pandemic by country

Vaccination in the United States

Respiratory syncytial virus vaccine

COVID-19 vaccine

Vaccine

Advisory Committee on Immunization Practices

Deployment of COVID-19 vaccines

Moderna

Click the tags to see associated articles and topics

CDC Meeting on RSV Vaccines Could Be Pivotal for GSK, Moderna | Barron's. View article details on HISWAI: https://www.barrons.com/amp/articles/gsk-moderna-stock-rsv-vaccines-26e5f86b

Summary

The article discusses the impact of upcoming CDC recommendations on the RSV vaccine market, highlighting the implications for GSK, Moderna, and Pfizer amidst public health considerations during the second respiratory virus season.

Article found on: www.barrons.com

View Original Article